We report a case with a germline mutation of the p53 gene develpoing both a non-Hodgkin's lymphoma andan astrocytoma. Theastrocytoma could be cured bytwo operations andcombined chemotherapy but 33 months afterthe onsetof the disease, he suffered from a diffuse, large cell centroblastic malignant lymphoma of B-cell lineage. In spite of clear rearranged fragments observed with IgH and c-MYC gene probes, we could not diagnose a Burkitt's lymphoma morphologically. Themalignant lymphoma waschemoresistant andthepatient diedof multi-organ failure. He wasconfirmed to have a germline mutation of the p53 geneby analysis of c-DNA from peripheral lymphocytes and loss of heterozygosity (LOH) of p53 was evident in the lymphoma. The results were suggestive of the Li-Fraumeni syndrome (LFS), a rare autosomal dominantly inherited syndrome witha germline mutation of p53 geneanddiverse malignancies, butthiscould not be confirmed in the present case. Alternatively, a de novo mutation could have been involved.
INTRODUCTION CASE REPORT
It is well known that the p53 is a tumor suppressor gene, often inactivated by deletion or point mutation in many types of solid tumors and blood malignancies (1) (2) (3) (4) (5) (6) (7) (8) . A strong correlation has been reported between p53 mutations and loss of chemosensitivity (9) (10) (11) . A gennline mutation ofthe p53 gene has been reported in a cancer-prone family, described as the Li-Fraumeni syndrome (LFS) (12) (13) (14) (15) (16) . Here, we report a case of a male patient with ap53 gene gennline mutation developing both an astrocytoma and a non-Hodgkin's lymphoma.
The patient was a 30-year-old Japanese male. He was operated on for a brain tumor in September 1993, this being histologically diagnosed as an anaplastic astrocytoma. Subsequently, he received anticancer chemotherapy (interferon-B. nimustine), but recurrence was found in February 1994 and a second operation was performed, Chemotherapy with cisplatin and etoposide was then continued with no recurrence of the brain tumor. Thirty-three months after the onset of astrocytoma, he complained of epigastric discomfort and abdominal fullness in March 1996. He was diagnosed as suffering from a diffuse, large cell centroblastic variant (WHO) malignant lymphoma of B-cell lineage from examination of biopsy material from the peritoneal tumor.
After the diagnosis, he received chemotherapy. At first, a VEPA regimen (adriamycin, cyclophosphamide, vincristine, prednisolone) was tried but tumor regression was transient and therefore irinotecan and a CNOP regimen (cyclophosphamide, mitoxantrone, vincristine, prednisolone) were applied. However, these therapies were not effective and finally he died of multi-organ failure (Fig. 1) .
MAGNETIC RESONANCE IMAGING (MRI) OF THE BRAIN
MRl revealed a cystic brain tumor (6 em in diameter) in the left temporal lobe with a mural nodule that was strongly enhanced by gadolinium (Fig . 2) . After the second operation, no recurrence of the brain tumor was detected (Fig . 2) . regular-shaped nuclei was prominent (Fig. 3) . Nuclear atypism might have been caused by the previous radiation therapy.
HISTOPATHOLOGICAL FINDING OF THE BRAIN TUMOR
In the specimens obtained at the first resection, the tumor was richly supplied by blood vessels and composed of thickly clustered cells and spindle-shaped cells (Fig. 3) . These tumor cells showed nuclear atypism and high mitotic activity and were immunoreactive for glial fibrillary acidic protein (GFAP). Thus the tumor was diagnosed as an anaplastic astrocytoma. In the tissue removed at the second operation, cellular pleomorphism with multinucleated giant cells containing hyperchromatic ir- Abdominal CT showed massive ascites and giant mass of convoluted mesenterium (Fig. 4) . PET showed uptake of fluorodeoxyglucose in the tumor (Fig. 4) and Ga-scinti showed a hot lesion broadly disseminated in the abdomen ( .~. ' .
•~I add(7) (q22), add(l4) (q32), -15, add(l7) (pll) and add(l8) (q23) (Fig. 6 ). To obtain a definite diagnosis, a biopsy was taken of the peritoneal tumor. The tumor cells were round-shaped, ranging from 12 to IS urn in diameter and had polymorphi c nuclei with a few distinct nucleoli and relatively abundant cytoplasm. Cytoplasmic droplets were rarely seen on Giemsa staining (Fig. 7) . Electron microscopic examination clearly defined these as lipid (Fig. 7) , The tumor cells showed CD 10+,CD 19+,CD20+, CD22+, CD38+, CD4S+,IgG+and IgL~by both flow cytometry and immunohistochemistry of frozen sections. Rearranged bands were detected by Southern blot analysis with probes for the IgH and kappa light chain genes as well as the c-MYC gene. Other probes used showed germline configurations. In spite of the CD 10 positivity and clear rearranged fragments with c-MYC probe, we could not diagnose this patient as having a 'Burkitt's lymphoma ' because of the atypical proliferation pattern and cellular morphology. He was diagnosed as suffering from a diffuse, large cell centroblastic variant (WHO) malignant lymphoma of B-cell lineage.
•

EXAMINATION OF p53
We first analysed p53 cDNA from the patient's lymphocytes using a yeast-based functional assay (FASAY) which has been used to detect heterozygous p53 mutations (17) . As shown in Fig.   8 , only 60% of transform ants showed a His" phenotype (control lymphocytes : 96%), indicating the presence of a heterozygous mutation of the p53 gene. Sequence analysis demonstrated a functionally inactivating heterozygous missense mutation , C242Y (Fig. 8) in the lymphocytes. To confirm inactivation of both alleles of p53 in the tumor, polymerase chain reaction-restriction length polymorphism analysis (PCR-RFLP) was performed using a set of primers (see caption to Fig. 8 ) which generated a lOSbp fragment containing a novel PstI site at codons 242 and 243. As shown in Fig. 6 , the PCR product from the patient 's lymphocytes was partially digested by PstI, generating both a digested fragment (82 bp) and an undigested fragment (lOS bp) because of the heterozygous mutation at codon 242 (lane 2). The PCR product derived from his lymphoma tissue retained the mutant p53 allele. Whereas that from his mother's lymphocytes was completely digested by PstI, indicating the lack of any germline p53 mutation (lane 1). We also examined 17 autopsy specimens including cerebrum, cerebellum, spinal cord, skin, tongue, esophagus , stomach, small intestine, lung, heart, liver, kidney, adrenal gland, bone marrow, aorta, muscle and adipose tissue by PCR-RFLP analysis and confirmed the heterozygous p53 mutation in all cases (data not shown).
AUTOPSY FINDINGS
There was thickening and fibrous adhesion of the whole peritoneum, 2-8 em in thickness, involving the entire intestines, liver and urinary bladder. Swelling of the mesentrial and parapancreatic lymph nodes was observed up to I em in diameter. No recurrence of the astrocytoma in the left temporal lobe of the cerebrum was apparent.
DISCUSSION
In the present case, the patient suffered from astrocytoma and malignant lymphoma at a young age and he had a germline mutation of p53 gene and LOH of p53 was shown in the ..~. lymphoma tissue. This finding suggests a strong link between a gennline mutation of the p53 gene and the astrocytoma and non-Hodgkin's lymphoma development. Gennline mutations of the p53 gene have been reported in cancer-prone families. The Li-Fraumen i syndrome (LFS) is a rare autosomal dominantly inherited syndrome with the following familial characteristics : a proband with either acute lymphocytic leukemia, sarcoma, breast cancer, brain tumor and/or adrenocortical carcinoma before the age of 45; a first-degree relative with a cancer in this group; and a first-or second-degree relative with sarcoma at any age or any cancer before age 45. The affected individuals have a gennline mutation of p53 (12) (13) (14) (15) (16) . The prevalence of a gennline p53 mutation is approximately 0.01% in the general population, but is 5-10% among young patients with multiple cancers. For example, in one study examini ng 59 child ren and young adults who would not otherwise be considered as having LFS, but who had developed two malignancies, the overall frequency of gennline p53 mutations was -7% (18, 19) .
In this case, his mother suffered from breast cancer at 36 years of age but her gennline p53 was wild type. The p53 status of the father was unknown but he was free of neoplasia. As far as we could determine, there was no other family history of malignancies excep t for the mother 's brother (rectal cancer). We could not diagnose him as LFS. If he had not died at a young age, he might have been shown to be a LFS proband .
It is well known that the p53 is a tumor suppressor gene often inactivated in many types of solid tumors and blood malignancies (1) (2) (3) (4) (5) (6) (7) (8) . Several studies have shown that p53 can mediate apoptotic cell death and that it is required for efficient activation of apoptosis following irradiation or chemotherapy (9-11). There is a clear link between p53 gene mutation and aggressive tumor behavior and a poor prognosis, in some cases associated with activation of the MD Rl (multidrug resistance) gene (20) . With regard to hematological malignancies, a strong correlation has been found between p53 mutations and chemosensitivity in AML, MDS and eLL (21) . It has recently been reported that non-Hodgkin 's lymphomas with a p53 abnorma lity are more likely to be drug resistant but that does not correlate with any other particular clinical characteristic (22) . A similar situation appears to be the case for some types of B-cell lymphomas (23, 24) . Regarding brain tumors, p53 gene mutations have been examined in astrocytomas, glioblastomas and some other tumors (25) (26) (27) (28) . In anaplastic astrocytomas and glioblastomas, almost 30--40% were found to be positive (26, 28) . In our survey of p53 gennline mutations in brain tumors, we found a case of a yolk sac carcinoma that demonstrated an additiona l mutation, known to lead to functional alteration of p53 protein (29) .
It has been reported that the presence of both p53 inactivation and The present case of a p53 germline mutaion in an individual developing both an astrocytoma and a non-Hodgkin's lymphoma appears not to represent LFS but rather a de novo change in the gene.
